Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib

Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Medicina (Kaunas)
Главные авторы: Brunetti, Oronzo, Gnoni, Antonio, Licchetta, Antonella, Longo, Vito, Calabrese, Angela, Argentiero, Antonella, Delcuratolo, Sabina, Solimando, Antonio Giovanni, Casadei-Gardini, Andrea, Silvestris, Nicola
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2019
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6843290/
https://ncbi.nlm.nih.gov/pubmed/31640191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55100707
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы